

Info Sheet for Technical description

No. XXXX (事務局付番)

Organization

* Mandatoty fields

Name of Organization*	MATRIXOME, Inc.	
Address, City, States, Zip, Country*	3-2 Yamadaoka, Suita, Osaka 565-0871 Japan Institute for Protein Research, Osaka University	
URL	https://matrixome.co.jp/en/	
Brief Descriptions of Organization* (Approx. 100 words)	"Matrixome" is a novel term proposed by Professor Kiyotoshi Sekiguchi, at Osaka University. The term 'matrixome' is a subset of the proteome to define whole collections of extracellular matrix molecules that constitute the customized microenvironments of individual cell types. Under this concept, Matrixome, Inc. was established to conduct research on the matrixome and its applications. MATRIXOME, Inc. contributes to the discovery and development of regenerative medicine by providing Laminin-E8 fragment products and the matrixome technology to the global market.	
Contact address	Name*	Yoichi Tsuyama
	Department* / Position	Domestic Sales Division / Manager
	E-mail* / TEL	y-tsuyama@matrixome.co.jp / +81-6-6877-0222

What kind of technology do you want to offer? *

- A.** Clinical Development Pipelines → Please see **Sheet [A]**
- B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- Yes
- No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- Angel / Seed (including AMED/JST grants)
- Series A
- Series B
- Series C
- Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
<input checked="" type="checkbox"/> Yes	
<input type="checkbox"/> No	

Filled in by*

Yoichi Tsuyama

Date*

20. Sep, 2023

Sheet [B] Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.**Info Sheet for Technical overview**

No. XXXX (事務局付番)

* Mandatoty fields

Title***iMatrix products contribute to regenerative medicine with cell culture substrates.****Category***

- | | | |
|---|--|---|
| <input type="checkbox"/> Facilities | <input type="checkbox"/> Manufacturing equipment | <input type="checkbox"/> Inspection equipment |
| <input type="checkbox"/> Cells | <input type="checkbox"/> Culture medium | <input checked="" type="checkbox"/> Reagents |
| <input type="checkbox"/> Cell banking | <input type="checkbox"/> Storage / Container | <input type="checkbox"/> Logistics |
| <input type="checkbox"/> Cell / Viral vector manufacturing technology | | |

Description*

iMatrix-511, iMatrix-511silk, iMatrix-511MG, iMatrix-411, iMatrix-221, iMatrix-221MG
 We sell iMatrix products, which are highly purified products of laminin E8 fragments.
 iMatrix products are substrates that can be used as a coating on cell culture equipment or added to cell suspensions.
 Laminin, a type of extracellular matrix protein, determines cell fate by adhering and interacting with cells. We succeeded in recombinantly purifying only the region of laminin that contains the cell-adhesive region (E8 region) and commercialized it.

Filled in by***Date***

Yoichi Tsuyama

20. Sep, 2023